Related Experiment Video
Updated: Mar 18, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Drugs under preclinical and clinical study for treatment of acute and chronic lymphoblastic leukemia
Joe Antony Jacob1, Jumah Masoud Mohammad Salmani1, Baoan Chen1
1Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China.
Abstract:
Targeted therapy has modernized the treatment of both chronic and acute lymphoblastic leukemia. The introduction of monoclonal antibodies and combinational drugs has increased the survival rate of patients. Preclinical studies with various agents have resulted in positive outputs with Phase III trial drugs and monoclonal antibodies entering clinical trials. Most of the monoclonal antibodies target the CD20 and CD22 receptors. This has led to the approval of a few of these drugs by the US Food and Drug Administration. This review focuses on the drugs under preclinical and clinical study in the ongoing efforts for treatment of acute and chronic lymphoblastic leukemia.
Insights
Targeted therapies, including monoclonal antibodies, are improving survival rates for acute and chronic lymphoblastic leukemia. This review examines emerging drugs in preclinical and clinical studies for leukemia treatment.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Targeted therapy has significantly advanced acute and chronic lymphoblastic leukemia treatment.
- Monoclonal antibodies and combination drugs have improved patient survival rates.
Purpose of the Study:
- To review drugs in preclinical and clinical studies for acute and chronic lymphoblastic leukemia.
- To highlight advancements in targeted therapies for leukemia.
Main Methods:
- Review of preclinical studies and clinical trials.
- Focus on monoclonal antibodies targeting CD20 and CD22 receptors.
- Analysis of FDA-approved and investigational agents.
Main Results:
- Positive outcomes in preclinical studies for various agents.
- Monoclonal antibodies and Phase III drugs are advancing to clinical trials.
- Several CD20 and CD22 targeting antibodies have received FDA approval.
Conclusions:
- Targeted therapies, particularly monoclonal antibodies, are revolutionizing leukemia treatment.
- Ongoing research and clinical trials are expanding therapeutic options for lymphoblastic leukemia.
- The development of novel agents shows promise for improved patient outcomes.
